In short
IPN60300 is an investigational protein-based substance being studied as a potential treatment for adults with locally advanced or metastatic solid tumours. It is given by intravenous infusion and has no marketing authorisation, meaning it is not yet approved as a medicine. One authorised Phase 1/2 trial is currently investigating its safety, tolerability, and early signs of antitumour activity in 118 participants.
Key points
- IPN60300 is an investigational protein-based substance with no marketing authorisation.
- It is being studied in advanced or metastatic solid tumours in adults.
- The trial is a Phase 1/2 study with an estimated 118 participants.
- IPN60300 is given as a solution for infusion by the intravenous route.
- The trial is currently authorised and sponsored by Ipsen Pharma.
What is IPN60300?
IPN60300 is an investigational protein-based substance being developed for the treatment of advanced or metastatic solid tumours. It is not currently authorised as a medicine and is available only within clinical research. The substance is supplied by Ipsen Pharma and appears under the single product name IPN60300 in the registry records.
How does IPN60300 work?
The registry records do not provide a detailed description of the molecular target or mechanism of action for IPN60300. The trial is designed to assess safety, tolerability, pharmacokinetics (how the body absorbs, distributes, and clears the drug), pharmacodynamics (the effects the drug has on the body), immunogenicity (whether the immune system reacts against the drug), and antitumour activity.
Which conditions is it studied for?
- Advanced or metastatic solid tumours — cancers that have grown locally or spread to other parts of the body and cannot be removed by surgery alone.
How is IPN60300 given?
IPN60300 is prepared as a solution for infusion and is given by the intravenous route, meaning it is administered directly into a vein. The trial uses IPN60300 as a single agent (test substance).
What do the clinical trials show?
One authorised Phase 1/2 trial (EU CT number 2025-522139-33-00) is investigating IPN60300 in adults with locally advanced or metastatic solid tumours. The study has an estimated enrollment of 118 participants. The trial is interventional and is divided into two parts: Phase Ia evaluates safety and tolerability of IPN60300 as a single agent and determines the maximum tolerated dose (MTD) or maximum administered dose (MAD) in participants with tumour types of interest; Phase Ib aims to determine the optimal dosing regimen in participants with selected tumours.
The primary outcomes include the percentage of participants with dose limiting toxicity (DLT) within 21 days after study drug administration in Phase Ia, the percentage of participants experiencing treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TE-SAEs) from the first administration until 30 days after the last dose in Phases Ia and Ib, and the objective response rate (ORR), defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST version 1.1, in Phase Ib.
What side effects are known?
No side effect data from supplementary sources are available for IPN60300. The trial is designed to collect information on treatment emergent adverse events and serious adverse events, which will provide the first safety profile for this substance.
